Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-FAP-2886
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[177Lu]Lu-FAP-2886 is a targeted radioligand therapy (RLT) comprising the beta-emitting radioisotope lutetium-177 conjugated to FAP-2886, a peptide ligand with high affinity for Fibroblast Activation Protein (FAP). FAP is a cell-surface serine protease that is significantly upregulated in the tumor microenvironment, specifically on cancer-associated fibroblasts (CAFs) and certain malignant cells like those in glioblastoma, while remaining largely absent in healthy adult tissues. By binding to FAP, [177Lu]Lu-FAP-2886 delivers ionizing radiation directly to the tumor site, causing lethal DNA damage to both the cancer cells and the supportive stroma. Developed by Perceptive, this agent is being investigated for its potential to treat aggressive solid tumors, including glioblastoma, where it has shown preclinical efficacy in xenograft models.
- Other names
- 177Lu-FAP-2886
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on [177Lu]Lu-FAP-2886.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-FAP-2886.